Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial

Xiaoran Fu1,2, Diego Iglesias-Álvarez3, Ana García-Campos3,4

  • 1Translational Cardiology Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.

Insights

Heart failure (HF) and atrial fibrillation (AF) share inflammatory and adiposity markers. Combined HF and AF show elevated stretch and fibrosis markers, suggesting a key role for the adiposity-fibrosis pathway.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathophysiology

Background:

  • The coexistence of heart failure (HF) and atrial fibrillation (AF) significantly worsens patient prognosis.
  • Understanding the underlying biological mechanisms linking HF and AF is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate inflammation, metabolism, adiposity, and fibrosis markers in epicardial and subcutaneous fat and plasma.
  • To explore the relationship between these markers and the presence of HF and/or AF.

Main Methods:

  • Analysis of multi-markers in fat biopsies and plasma from 185 cardiac surgery patients.
  • Grouping patients based on the presence of HF or AF.
  • Statistical analysis to identify predictors and correlations.

Main Results:

  • Increased plasma adiposity markers were observed in AF patients.
  • Elevated stretch markers correlated with HF.
  • Patients with both AF and HF exhibited higher levels of ANP and GDF-15.
  • Plasma FABP4 emerged as a key HF predictor after excluding AF.
  • Fat biopsies from AF patients revealed an enhanced inflammatory profile.

Conclusions:

  • Higher adiposity markers are associated with AF or HF individually.
  • Increased stretch and fibrosis markers are linked to the combined presence of AF and HF.
  • The adiposity-fibrosis pathway is implicated in the coexistence of HF and AF.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
20
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K